trial

Research Into Antipsychotic Discontinuation and Reduction Trial

NCTId NCT03559426
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 253 (actual)
Sponsored by University College, London
Primary completion 2022-03-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
253 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2016-03-24
Primary completion
2022-03-10
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Antipsychotic ReductionAripiprazole

Sponsors

University College, LondonLead Sponsor

Investigators

1
Joanna Moncrieff, MBBSPrincipal Investigator

Sites

1 total
London, United Kingdom

Facts & assertions

4 sourced
Enrollment
253
Phase
PHASE4
Primary Completion Date
2022-03-10
Status
COMPLETED
relationships
The graph out of here
drug
Antipsychotic Reduction
drug
Aripiprazole
drug
lead_sponsor
University College, London
company
indication
Schizophreniform Disorders
indication
Schizoaffective Disorder
indication
Schizophrenia, Paranoid
indication
investigator
Joanna Moncrieff, MBBS
person